General Background: The Research Network Ltd was founded in 2011 and provides Pharmaceutical R&D scientific consultancy, project management, outsourcing, training and due diligence services. Our experienced team has in-depth expertise across the key drug discovery and development disciplines covering both small molecule and biotherapeutics. We also collaborate with Universities and research organisations to progress new drug discovery ventures from lead identification through early clinical development.
Genesis Focus: We’re looking forward to discussing our insights with others, as well as hearing from key opinion leaders with a view to identifying opportunities to collaborate and tackle challenges present in the life science sector. TRN’s dedicated to enabling drug discovery and development and hopes to meet likeminded groups at Genesis to work with.
News: TRN has spun out several venture companies over the past few years, most notably EmstoPA Ltd, who are developing a humanised monoclonal antibody fragment for the treatment of bleeding complications in patients who have received tPA, the “clot buster” used to treat stroke. The availability of an antidote to address possible intracranial bleeding caused by tPA, the current gold standard treatment for ischemic stroke, has the potential to save lives and reduce disability in multiple patients worldwide.